文献速递主动脉疾病

EVAR术中及随访期瘤囊旁动脉栓塞的中期评估

Midterm evaluation of perigraft arterial sac embolization in endovascular aneurysm repair.
PubMed 文献 · J Vasc Surg · 2020-05-26

该研究回顾性分析两家机构2006至2016年共66例EVAR后接受瘤囊旁动脉栓塞(PASE)的患者,其中初次PASE 38例(58%)、二次PASE 28例(42%)。结果显示PASE对I型内漏成功率88%、II型73%,无靶向外栓塞等安全事件,4例(6%)因残余高压内漏需开放修复。

要点

  • PASE对I型内漏成功率88%,II型73%,可作为EVAR瘤囊管理的辅助手段。
  • 队列中无靶向外栓塞、脊髓缺血、过敏反应、EVAR后破裂或结肠缺血发生。
  • 4例(6%)因残余高压内漏需开放修复,其余患者随访期瘤囊未增长。

核心结论

  • 初次与二次PASE均是EVAR瘤囊管理中安全、有效且持久的工具。
  • PASE治疗EVAR术中或术后的内漏可减少CT上的内漏发生率并阻止瘤囊增长。
  • PASE减少EVAR后再干预的长期持久性仍需进一步研究确认。

研究设计与样本

  • 回顾性审查前瞻性维护的数据库,数据来自两家机构2006至2016年。
  • 共66例患者接受PASE,初次38例(58%),二次28例(42%)。
  • PASE使用凝血酶、对比剂与Gelfoam制成的浆液,用于I、II或III型内漏。
  • 平均临床与CT随访1.7年(0.1-11.6年)。

主要发现

  • 4例(6%)因残余高压内漏需开放修复(1例IIIB型、3例I型)。
  • 未需开放转换的95%患者在随访期内未出现瘤囊增长。
  • PASE对I型内漏成功率为88%,对II型内漏为73%。
  • 内漏责任血管血栓形成后无再通证据。
  • 无患者发生靶向外栓塞、脊髓缺血、过敏反应、EVAR后破裂或结肠缺血。

关键数值与推荐

  • 成功率:I型内漏88%,II型内漏73%。
  • 需开放修复者占6%(4/66)。
  • 未需开放转换者占95%,随访期无瘤囊增长。
  • 平均随访1.7年(范围0.1-11.6年)。

临床怎么用

  • 可在EVAR术中或随访发现I、II、III型内漏时采用PASE处理。
  • PASE后需通过增强CT随访评估内漏是否消退及瘤囊是否增长。
  • 对残余高压内漏需警惕并评估开放修复的可能。

局限性

  • 为回顾性研究,样本量66例,随访时间有限。
  • PASE长期持久性及减少二次干预的效果尚需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Management of clinically significant endoleaks (ELs) remains costly, time-consuming, and morbid. Unresolved ELs can result in rupture and mortality after endovascular aneurysm repair (EVAR). Perigraft arterial sac embolization (PASE) has been used to treat ELs diagnosed at the time of EVAR or during surveillance. METHODS: A retrospective review of prospectively maintained databases was conducted. The databases were compiled from two institutions between 2006 and 2016. PASE was performed for type I, type II, or type III EL with a thrombin, contrast medium, and Gelfoam (Pfizer, New York, NY) slurry prepared as previously described. PASE was administered either at the time of EVAR (primary) or during surveillance (secondary). Safety end points included nontarget embolization, defined as neurologic or enteric clinical sequelae from lumbar artery or visceral artery embolization, allergic reaction, peripheral embolization, or rupture. Efficacy end points included successful resolution of EL and cessation of aneurysm sac growth on computed tomography (CT) scans with contrast enhancement. RESULTS: A total of 66 patients included in the study were treated with PASE. Primary PASE was performed in 38 patients (58%) and secondary in 28 (42%). Within the total cohort, the average clinical and CT scan follow-up was 1.7 years (0.1-11.6 years). Four patients required open repair for residual high-pressure ELs (one type IIIB and three type I; 6%). Of the 95% of patients who did not require open conversion, aneurysm growth did not occur during the follow-up period. In the overall cohort, PASE was successful in 88% of type I EL and 73% of patients with type II EL. There was no evidence of recanalization after thrombosis of culprit vessel for EL. No patients suffered nontarget embolization, spinal ischemia, allergic reaction, post-EVAR rupture, or colonic ischemia. CONCLUSIONS: Primary and secondary PASE proved to be a safe, effective, and durable tool in sac management in conjunction with EVAR. Treating ELs during or after EVAR with PASE has minimized the incidence of EL on CT scan and halted aneurysm growth in our cohort. Further studies are needed to confirm the long-term durability of PASE in reducing secondary interventions after EVAR.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Barleben A, Quinones-Baldrich W, Mogannam A, et al. Midterm evaluation of perigraft arterial sac embolization in endovascular aneurysm repair. J Vasc Surg. 2020. PMID: 32471739. doi:10.1016/j.jvs.2020.01.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。